Isabelle Rosa
French Institute of Health and Medical Research
71 Papers
472 Citations
Isabelle Rosa is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Medicine & Ribavirin. The author has an hindex of 23, co-authored 63 publications. Previous affiliations of Isabelle Rosa include University of Paris.
Chat about Author
Papers
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Fabrice Carrat,Hélène Fontaine,Céline Dorival,Mélanie Simony,Alpha Diallo,Christophe Hézode,Victor de Ledinghen,Dominique Larrey,Georges Haour,Jean-Pierre Bronowicki,Fabien Zoulim,Tarik Asselah,Patrick Marcellin,Dominique Thabut,Vincent Leroy,Albert Tran,François Habersetzer,Didier Samuel,Dominique Guyader,Olivier Chazouillères,Philippe Mathurin,Sophie Metivier,Laurent Alric,Ghassan Riachi,Jérôme Gournay,Armand Abergel,Paul Calès,Nathalie Ganne,Véronique Loustaud-Ratti,Louis d’Alteroche,Xavier Causse,Claire Geist,Anne Minello,Isabelle Rosa,Moana Gelu-Simeon,Isabelle Portal,François Raffi,Marc Bourlière,Stanislas Pol +38 more
TL;DR: Treatment with direct-acting antivirals is associated with reduced risk for mortality and hepatocellular carcinoma and should be considered in all patients with chronic HCV infection.
550
Liver stiffness diminishes with antiviral response in chronic hepatitis C.
Christophe Hézode,Laurent Castera,Françoise Roudot-Thoraval,Françoise Roudot-Thoraval,Magali Bouvier-Alias,Magali Bouvier-Alias,Isabelle Rosa,Dominique Roulot,Vincent Leroy,Ariane Mallat,Ariane Mallat,Jean-Michel Pawlotsky,Jean-Michel Pawlotsky +12 more
TL;DR: Aliment Pharmacol Ther 2011; 34: 656–663.
137
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Stanislas Pol,Marc Bourlière,Sandy Lucier,Christophe Hézode,Céline Dorival,Dominique Larrey,Jean-Pierre Bronowicki,Victor de Ledinghen,Fabien Zoulim,Albert Tran,Sophie Metivier,Jean-Pierre Zarski,Didier Samuel,Dominique Guyader,Patrick Marcellin,Anne Minello,Laurent Alric,Dominique Thabut,Olivier Chazouillères,Ghassan Riachi,Valérie Bourcier,Philippe Mathurin,Véronique Loustaud-Ratti,Louis d’Alteroche,Isabelle Fouchard-Hubert,François Habersetzer,Xavier Causse,Claire Geist,Isabelle Rosa,Jérôme Gournay,Eric Saillard,Eric Billaud,Ventzislava Petrov-Sanchez,Alpha Diallo,Hélène Fontaine,Fabrice Carrat +35 more
TL;DR: The sofosbuvir+daclatasvir combination of antiviral drugs is associated with a high rate of SVR12 in patients infected by genotype 1, with an optimal duration of 12weeks in non-cirrhotic patients and 24weeks for those with cirrhosis.
124
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta.
Dominique Roulot,Ségolène Brichler,Richard Layese,Zahia Ben-Abdesselam,Fabien Zoulim,Vincent Thibault,Caroline Scholtes,Bruno Roche,Corinne Castelnau,Thierry Poynard,Olivier Chazouillères,Nathalie Ganne,Hélène Fontaine,Jérôme Gournay,Dominique Guyader,Frédéric Le Gal,Pierre Nahon,Françoise Roudot-Thoraval,Emmanuel Gordien,Jean-Didier Grangé,Roland Landman,Christophe Hézode,Ghassan Riachi,Caroline Lascoux-Combe,Véronique Loustaud-Ratti,Isabelle Rosa,Philippe Mathurin,Eric Nguyen-Khac,Xavier Causse,Sylvie Naveau,François Habersetzer,Sophie Metivier,H. Labadie,P. Sellier,Julie Bottero,Victor de Ledinghen,Laurent Alric,Paul Calès,Cécile Goujard,Jean-François Cadranel,Dominique Salmon,Sophie Hillaire +41 more
TL;DR: Place of birth, HDV genotype and persistent viremia constitute the main determinants of liver involvement and response to treatment in chronic HDV-infected patients.
117
Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States.
Benjamin Cadier,Julie Bulsei,Pierre Nahon,Pierre Nahon,Olivier Seror,Alexis Laurent,Isabelle Rosa,Richard Layese,Charlotte Costentin,Carole Cagnot,Isabelle Durand-Zaleski,Karine Chevreul +11 more
TL;DR: It is indicated that gold‐standard monitoring for patients with cirrhosis is cost‐effective, attributed to a higher probability of benefiting from a curative treatment and so a higher survival probability.
112